Poll: Vote on the Top GI Cancer Abstracts to Watch at ESMO 2025

The 2025 European Society of Medical Oncology (ESMO) Congress in Berlin, Germany, begins on October 17. This year, several late-breaking abstracts (LBAs) across gastrointestinal (GI) malignancies are poised to be practice-changing.

To find out which LBAs are most important to Targeted Oncology readers, we’re launching a series of polls to identify the most exciting research results in colorectal cancer (CRC), hepatocellular carcinoma (HCC), gastroesophageal (GE) cancer, and more. Voting is now open on LinkedIn, X, and Facebook through October 8, 2025.

What Are the Top Abstracts to Watch in CRC at the ESMO 2025 Congress?

Poll 1: Which of these CRC abstracts are you most anticipating at ESMO 2025?

Vote Now: LinkedIn | X | Facebook

1. LBA29 - Nivolumab plus ipilimumab vs nivolumab monotherapy for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic CRC ( mCRC): new results from CheckMate 8HW

2. LBA30 - Zanzalintinib plus atezolizumab (zanza + atezo) vs regorafenib (rego) in patients (pts) with previously treated mCRC: Primary overall survival (OS) analysis from the randomized, open-label, phase 3 STELLAR-303 study

3. LBA32 - Panitumumab retreatment followed by regorafenib versus the reverse sequence in chemorefractory metastatic CRC patients with RAS and BRAF wild-type circulating tumor DNA (ctDNA): Final results of the randomized PARERE trial by GONO

4. LBA33 - ctDNA-guided anti-EGFR rechallenge strategy in mCRC: Final results of the phase II randomized CITRIC trial

What Are the Top Abstracts to Watch in HCC at the ESMO 2025 Congress?

Poll 2: Which of these HCC abstracts are you most anticipating at ESMO 2025?

Vote Now: LinkedIn | X | Facebook

1. LBA50 - IMbrave152/SKYSCRAPER-14: a phase 3 study of first-line tiragolumab (tira) + atezolizumab (atezo) + bevacizumab (bev) vs placebo (pbo) + atezo + bev for patients (pts) with untreated locally advanced or metastatic HCC

2. LBA52 - Nofazinlimab combined with lenvatinib versus placebo plus lenvatinib as first-line therapy for unresectable or metastatic HCC: a phase 3, randomized, double-blind, multiregional study (CS1003-305)

3. LBA51 - IKF-035/ABC-HCC: A phase IIIb, randomized, multicenter, open-label trial of atezolizumab plus bevacizumab versus transarterial chemoembolization (TACE) in intermediate-stage HCC

What Are the Top Abstracts to Watch in GE Cancers at the ESMO 2025 Congress?

Poll 3: Which of these gastroesophageal cancer abstracts are you most anticipating at ESMO 2025?

Vote Now: LinkedIn | X | Facebook

1. LBA78 - KN026 in combination with chemotherapy for previously treated HER2-positive gastric or GE carcinomas: Interim analysis of KC-WISE

2. LBA79 - Lenvatinib plus pembrolizumab and chemotherapy vs pembrolizumab and chemotherapy in untreated metastatic esophageal squamous cell carcinoma: the randomized phase 3 LEAP-014 study

3. LBA80 - Regorafenib plus nivolumab vs investigator’s choice of chemotherapy in previously treated gastric or gastroesophageal cancer: INTEGRATE IIb, a randomized phase 3 AGITG Intergroup [NHMRC-CTC/IKF/AIO, ACCRU, TCOG/NHRI] study

4. LBA82 - Tislelizumab combined with induction chemotherapy and concurrent chemoradiotherapy in locally advanced esophageal squamous cell carcinoma: a multicenter, randomized, phase II trial (EC-CRT-002)

What Are the Top Abstracts to Watch in Other GI Cancers at the ESMO 2025 Congress?

Poll 4: Which of these abstracts in less common GI cancers are you most anticipating at ESMO 2025?

Vote Now: LinkedIn | X | Facebook

1. LBA11 - Neoadjuvant toripalimab plus lenvatinib and GEMOX in resectable, high-risk intrahepatic cholangiocarcinoma: a randomized, multicenter, open-label phase II-III clinical trial

2. LBA84 - Efficacy and safety of GFH375 monotherapy in previously treated advanced KRAS G12D-mutant pancreatic ductal adenocarcinoma (PDAC)

3. LBA85 - Results of a randomized phase 3 trial of short-course vs long-course preoperative chemotherapy for stage I-III PDAC

4. LBA63 - XT-XTR008-3-01: a phase III study of 177Lu-Dotatate vs high-dose octreotide long-acting repeatable (LAR) in patients with advanced grade 1–2, well-differentiated, gastroenteropancreatic neuroendocrine tumours (GEP-NETs)

By voting on these polls, you’ll help inform our coverage and bring you the most important news coming out of the ESMO 2025 Congress. The ESMO Congress offers a global oncology platform for clinicians, researchers, patient advocates, journalists, and healthcare industry representatives to meet, share, and learn about the latest in cancer care, from groundbreaking discoveries to cutting-edge treatments.

Polls are open through October 8, 2025. Share these with your peers and colleagues and get the discussion going.